The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy
CompletedPhase 2, Phase 3NCT02969733
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Recent clinical studies in abdominal surgery have shown that the use of Xylocaine® parenterally intraoperative at plasma concentrations below the toxic threshold of 5 .mu.g / ml, had an analgesic effect and decreased postoperative morphine consumption. This study aims to evaluate the activity of Xylocaine® and ketamine separately administered parenterally, in terms of postoperative morphine consumption and decrease incidences of postoperative chronic pain at 3 and 6 months after laparoscopic colectomy compared the placebo group. The evaluation of the intensity of postoperative pain, hyperalgesia perished skin surface scarring) and pain perception threshold by Pain Matcher® confirm or not the predictive nature of these criteria in the occurrence of chronic pain.
Study details
- Official title
- The Interest of the Xylocaine® and Ketamine on the Per and Postoperative Management of Acute and Chronic Postoperative Pain After Colectomy by Laparoscopy
- Conditions
- Interventions
- Drug: Xylocaine
- Drug: Ketamine
- Drug: isotonic saline serum intravenous administration
- Sponsor
- University Hospital, Lille
- Start date
- 2011-01
- Primary completion
- 2017-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Surgery: segmental or total colectomy performed by laparoscopy * Anesthesia state 1 and 3 Exclusion Criteria: * Patients classified Anesthesia state 4 or 5 * Allergy or intolerance to any of the products used in the protocol * Creatinine clearance calculated by the Cockcroft formula below 50 ml / min * Hepatocellular insufficiency * Severe heart failure * Peptic ulcer * Chronic inflammatory bowel disease (IBD) * Previous history of epilepsy or seizures * Surgery emergency, palliative surgery, revision surgery * Chronic pain requiring regular intake of analgesics include opioids * Patients treated with lidocaine patch * Psychic Disorder * Additive Conduct vis-à-vis alcohol or mind-altering substances * Pregnant or breastfeeding women
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02969733